Intravenous naftidrofuryl for critical limb ischaemia

Critical limb ischemia: Current and novel therapeutic strategies

“…When revascularization procedures have failed or for whom revascularization is not technically possible, particularly when amputation is the only alternative, a category of drugs called vasoactives could be one of the best alternatives (Smith, Bradbury, & Fowkes, 2012). Also, because there is a high incidence of coronary events and stroke in patients with peripheral arterial disease, the antiplatelet therapy has been recommended to minimize vascular events and increase survival of patients (Baigent et al, 2009;Committee, 1996).…”

Critical limb ischemia: Current and novel therapeutic strategies

“…When revascularization procedures have failed or for whom revascularization is not technically possible, particularly when amputation is the only alternative, a category of drugs called vasoactives could be one of the best alternatives (Smith, Bradbury, & Fowkes, 2012). Also, because there is a high incidence of coronary events and stroke in patients with peripheral arterial disease, the antiplatelet therapy has been recommended to minimize vascular events and increase survival of patients (Baigent et al, 2009;Committee, 1996).…”

Current review with evolving management strategies in critical limb ischemia

“…[33] Use of vasodilators such as iloprost (prostanoids) or naftidrofuryl has also been tried but with variable results. [34] Cilastazol (phosphodiesterase III inhibitor having antiplatelet, vasodilator, and antimitogenic properties) has been shown to favorably increase skin perfusion pressure and wound healing in patients with CLI. [35] Use of oral cilostazol (dosage of 100 mg twice daily), in addition to best medical therapy has resulted in improvement in nearly a quarter of patients with nonreconstructable CLI; however, further studies are required to adequately evaluate its role in these patients.…”

Revascularization Techniques for Limb Salvage in Critical Limb Ischemia: A Single Institutional Study From Pakistan

“…Chronic lower limb ischemia has a global prevalence of approximately 202 million, making it one of the most common causes of presentation to the vascular surgeon [1]. An estimated 25% of these patients will develop critical limb ischemia (CLI) [2]. The Trans-Atlantic Society of Cardiovascular Surgery (TASC) defines critical limb ischemia as a chronic process characterized by the presence of ischemic ulcer necrosis or rest pain, limb-threatening ischemia (necessitating amputation within six months), as well as certain specific ankle and toe pressure thresholds [3].…”

Critical limb ischemia: Current and novel therapeutic strategies

“…When revascularization procedures have failed or for whom revascularization is not technically possible, particularly when amputation is the only alternative, a category of drugs called vasoactives could be one of the best alternatives (Smith, Bradbury, & Fowkes, 2012). Also, because there is a high incidence of coronary events and stroke in patients with peripheral arterial disease, the antiplatelet therapy has been recommended to minimize vascular events and increase survival of patients (Baigent et al, 2009;Committee, 1996).…”

Current review with evolving management strategies in critical limb ischemia

“…[33] Use of vasodilators such as iloprost (prostanoids) or naftidrofuryl has also been tried but with variable results. [34] Cilastazol (phosphodiesterase III inhibitor having antiplatelet, vasodilator, and antimitogenic properties) has been shown to favorably increase skin perfusion pressure and wound healing in patients with CLI. [35] Use of oral cilostazol (dosage of 100 mg twice daily), in addition to best medical therapy has resulted in improvement in nearly a quarter of patients with nonreconstructable CLI; however, further studies are required to adequately evaluate its role in these patients.…”

Revascularization Techniques for Limb Salvage in Critical Limb Ischemia: A Single Institutional Study From Pakistan

“…Chronic lower limb ischemia has a global prevalence of approximately 202 million, making it one of the most common causes of presentation to the vascular surgeon [1]. An estimated 25% of these patients will develop critical limb ischemia (CLI) [2]. The Trans-Atlantic Society of Cardiovascular Surgery (TASC) defines critical limb ischemia as a chronic process characterized by the presence of ischemic ulcer necrosis or rest pain, limb-threatening ischemia (necessitating amputation within six months), as well as certain specific ankle and toe pressure thresholds [3].…”

Critical limb ischemia: Current and novel therapeutic strategies

“…When revascularization procedures have failed or for whom revascularization is not technically possible, particularly when amputation is the only alternative, a category of drugs called vasoactives could be one of the best alternatives (Smith, Bradbury, & Fowkes, 2012). Also, because there is a high incidence of coronary events and stroke in patients with peripheral arterial disease, the antiplatelet therapy has been recommended to minimize vascular events and increase survival of patients (Baigent et al, 2009;Committee, 1996).…”

Current review with evolving management strategies in critical limb ischemia

“…[33] Use of vasodilators such as iloprost (prostanoids) or naftidrofuryl has also been tried but with variable results. [34] Cilastazol (phosphodiesterase III inhibitor having antiplatelet, vasodilator, and antimitogenic properties) has been shown to favorably increase skin perfusion pressure and wound healing in patients with CLI. [35] Use of oral cilostazol (dosage of 100 mg twice daily), in addition to best medical therapy has resulted in improvement in nearly a quarter of patients with nonreconstructable CLI; however, further studies are required to adequately evaluate its role in these patients.…”

Revascularization Techniques for Limb Salvage in Critical Limb Ischemia: A Single Institutional Study From Pakistan

“…Chronic lower limb ischemia has a global prevalence of approximately 202 million, making it one of the most common causes of presentation to the vascular surgeon [1]. An estimated 25% of these patients will develop critical limb ischemia (CLI) [2]. The Trans-Atlantic Society of Cardiovascular Surgery (TASC) defines critical limb ischemia as a chronic process characterized by the presence of ischemic ulcer necrosis or rest pain, limb-threatening ischemia (necessitating amputation within six months), as well as certain specific ankle and toe pressure thresholds [3].…”